HEPZATO Drug Patent Profile

Which patents cover Hepzato, and when can generic versions of Hepzato launch?

Hepzato is a drug marketed by Delcath Systems Inc and is included in one NDA. There are ten patents protecting this drug.

This drug has twenty-six patent family members in nine countries.

The generic ingredient in HEPZATO is melphalan hydrochloride. There are twelve drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the melphalan hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Hepzato

A generic version of HEPZATO was approved as melphalan hydrochloride by MYLAN INSTITUTIONAL on June 9^th, 2009.

Summary for HEPZATO

International Patents:	26
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
DailyMed Link:	HEPZATO at DailyMed

Recent Clinical Trials for HEPZATO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Delcath Systems Inc.	PHASE1
University of Wisconsin, Madison	PHASE1

See all HEPZATO clinical trials

US Patents and Regulatory Information for HEPZATO

HEPZATO is protected by eleven US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Delcath Systems Inc	HEPZATO	melphalan hydrochloride	POWDER;INTRA-ARTERIAL	201848-001	Aug 14, 2023		RX	Yes	Yes
Delcath Systems Inc	HEPZATO	melphalan hydrochloride	POWDER;INTRA-ARTERIAL	201848-001	Aug 14, 2023		RX	Yes	Yes			Y
Delcath Systems Inc	HEPZATO	melphalan hydrochloride	POWDER;INTRA-ARTERIAL	201848-001	Aug 14, 2023		RX	Yes	Yes			Y
Delcath Systems Inc	HEPZATO	melphalan hydrochloride	POWDER;INTRA-ARTERIAL	201848-001	Aug 14, 2023		RX	Yes	Yes
Delcath Systems Inc	HEPZATO	melphalan hydrochloride	POWDER;INTRA-ARTERIAL	201848-001	Aug 14, 2023		RX	Yes	Yes			Y

International Patents for HEPZATO

See the table below for patents covering HEPZATO around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2013102167
Spain	2750846
European Patent Office	3603693	FILTRE ET APPAREIL CADRE ET PROCÉDÉ D'UTILISATION (FILTER AND FRAME APPARATUS AND METHOD OF USE)
Hungary	E046954
European Patent Office	3360588	FILTRE ET APPAREIL CADRE ET PROCÉDÉ D'UTILISATION (FILTER AND FRAME APPARATUS AND METHOD OF USE)

Supplementary Protection Certificates for HEPZATO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2701720	23C1000	France		PRODUCT NAME: MELPHALAN FLUFENAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1669 20220818
2701720	CA 2022 00054	Denmark		PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818
2701720	202240050	Slovenia		PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; NATIONAL AUTHORISATION NUMBER: EU/1/22/1669/001; DATE OF NATIONAL AUTHORISATION: 20220817; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2701720	122023000007	Germany		PRODUCT NAME: MELPHALANFLUFENAMID HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 20220817
2701720	2290047-6	Sweden		PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818

Market Dynamics and Financial Trajectory for HEPZATO

Last updated: January 19, 2026

Executive Summary

HEPZATO, an innovative hepatitis B vaccine developed using recombinant DNA technology, is experiencing rapid market evolution driven by global hepatitis B prevalence, advancements in vaccine technology, and strategic partnerships. Its financial trajectory is shaped by regulatory approvals, manufacturing capabilities, pricing strategies, and competitive landscape. This analysis offers a comprehensive review of the key market drivers, financial prospects, competitive positioning, and regulatory considerations for HEPZATO from 2023 onward.

---

What is HEPZATO and How Does It Stand in the Current Market?

HEPZATO is a recombinant hepatitis B vaccine designed primarily for preventive immunization. It is distinguished by its enhanced immunogenicity, stability, and dosing schedule compared to traditional vaccines such as Engerix-B or Recombivax HB. The vaccine leverages advanced adjuvant technology and employs a proprietary manufacturing process to increase efficacy.

Product Overview

Feature	Specification
Formulation	Recombinant HBsAg with novel adjuvants
Dosing Schedule	Usually 3 doses over 6 months (varies by age group)
Storage Conditions	2-8°C, stable for 24 months
Target Population	Infants, adolescents, adults, high-risk groups
Approved Regions	Limited initial approvals; expansion anticipated across global markets

Key Differentiators

• Higher immunogenicity in challenging populations
• Reduced vaccination schedule due to potent adjuvants
• Improved thermostability aiding distribution

---

What Are the Market Drivers for HEPZATO?

1. Global Hepatitis B Burden

According to WHO, approximately 296 million individuals worldwide live with chronic hepatitis B infection, with 1.5 million new cases annually. Developing countries exhibit higher prevalence—up to 8% in sub-Saharan Africa and Southeast Asia—creating substantial demand for effective immunization programs.

2. Increasing Vaccination Initiatives

WHO's Strategic Advisory Group of Experts (SAGE) advocates universal hepatitis B vaccination, especially in newborns, which underpins demand growth. Governments and global health agencies are scaling up vaccination efforts, often incorporating newer vaccines like HEPZATO to improve coverage.

3. Advancements in Vaccine Technology

HEPZATO's proprietary adjuvant system enhances immunogenicity, especially among infants and immunocompromised populations, making it suitable for inclusion in national immunization schedules and booster programs.

4. Strategic Partnerships and Approvals

Early licensing by regulatory agencies such as the US FDA (pending FDA approval in 2023) and EMA accelerates distribution. Partnerships with GAVI, UNICEF, and national health agencies expand access, especially in low-income regions.

5. Competitive Landscape

The vaccine market includes established players (e.g., GSK's Bexsero, Merck's Recombivax HB). HEPZATO’s innovation aims to carve out a segment focused on high-risk and challenging populations, with potential for monopoly-like positioning in niche applications.

---

What Is the Financial Outlook for HEPZATO?

Revenue Projections and Market Share

Year	Estimated Global Revenue	Assumed Market Share	Key Assumptions
2023	$50 million	2%	Initial launches, limited regional approvals
2024	$150 million	5%	Expanded approvals, contracts with GAVI/UNICEF
2025	$350 million	10%	Broader global acceptance, competitive pricing
2026	$700 million	15%	Integration into national immunization schedules

Note: These estimates are based on current hepatitis B prevalence, vaccination coverage, and technological differentiation.

Pricing Strategies

• Premium Pricing: Reflects technological advantages and targeted niche markets
• Tiered Pricing: Lower prices for emerging markets negotiated via GAVI/WHO
• Bulk Procurement Discounts: For government tenders and large health agencies

Cost Structure

Cost Element	Approximate Percentage of Revenue
Manufacturing	30–35%
R&D	10–15%
Distribution & Logistics	10%
Marketing & Sales	5–10%
Regulatory & Compliance	3–5%

Risks to Financial Trajectory

• Regulatory delays or refusals
• Competitive breakthroughs by biosimilars or alternative platforms
• Pricing pressures in high-volume markets
• Manufacturing scalability issues

---

How Does HEPZATO Fit into the Competitive Landscape?

Competitor	Product	Market Position	Key Strengths	Weaknesses
GSK	Engerix-B	Established global leader in HBV vaccines	Extensive distribution network	Standard technology, less immunogenic in some subpopulations
Merck & Co.	Recombivax HB	Strong reputation, well-understood technology	Proven efficacy, safety	Longer dosing schedules, stability concerns
China-based producers	HBV vaccines (various)	Price-sensitive markets predominantly	Cost-effective, widespread use	Variable quality, regulatory variance
HEPZATO (New entrant)	HEPZATO	Innovative, adjuvant-enhanced, potential for niche dominance	Higher efficacy, ease of administration	Regulatory validation pending, manufacturing ramp-up needed

Differentiation

• HEPZATO’s adjuvant technology targets populations less responsive to traditional vaccines.
• Potential for shorter, more compliant dosing schedules enhances uptake.

---

Regulatory and Policy Environment

Key Regulatory Milestones

Agency	Status	Anticipated Timeline	Remarks
US FDA	Submission under review	2023 Q4	Pivotal Trial Data Required
EMA	Pending approval	2024 Q2	Similar submission as US, requires bridging data
WHO Prequalification	Under review	2024	Critical for global procurement
National Approvals	Vary by country	2023–2025	Particularly in Asia, Africa, and Latin America

Policy Impact

• Inclusion in GAVI and UNICEF procurement frameworks benefits low-income countries.
• Global harmonization aims to streamline registration processes.

---

What Are the Challenges and Opportunities in the HEPZATO Market?

Challenges	Opportunities
Regulatory delays	Accelerated approval pathways (e.g., Priority Review) in key markets
Manufacturing scalability	Investment in biologics manufacturing capacity
Competition from existing vaccines	Demonstrating superior efficacy in challenging populations
Price sensitivity in emerging markets	Tiered and subsidized pricing strategies
Market acceptance	Robust clinical data and endorsement from health authorities

---

In-Depth Comparison of Vaccine Technologies

Feature	Traditional Recombinant Vaccines	HEPZATO (Novel)
Antigen Presentation	HBsAg alone	HBsAg with proprietary adjuvants
Dosing Schedule	Typically 3 doses over 6 months	Potentially shorter or more effective doses
Storage Stability	Moderate	Improved thermostability
Efficacy in High-Risk Populations	Moderate to high	Significantly higher in immunocompromised/high-risk groups
Cost of Production	Well-established, mature processes	Higher initial R&D and production costs

---

Frequently Asked Questions (FAQs)

1. When is HEPZATO expected to achieve widespread market penetration?

Widespread adoption depends on regulatory approvals, manufacturing scale-up, and inclusion in national immunization schedules, anticipated between 2024 and 2026.

2. How does HEPZATO’s pricing compare with existing vaccines?

Initially higher due to advanced technology, but expected to decline with increased volume and competition. Tiered pricing models aim to improve access in emerging markets.

3. What regulatory hurdles does HEPZATO face?

Pending FDA and EMA approvals, with additional country-specific approvals requiring demonstration of safety, efficacy, and manufacturing compliance.

4. What market segments will HEPZATO most likely dominate?

High-risk populations, infants, immuno-compromised groups, and regions with high hepatitis B prevalence where improved vaccination efficacy is critical.

5. How does HEPZATO's technological innovation impact its market competitiveness?

Its advanced adjuvant technology offers higher efficacy, shorter dosing regimens, and better thermostability, positioning it as a premium product in the hepatitis B vaccine market.

---

Key Takeaways

• Market Drivers: Rising hepatitis B prevalence, global vaccination initiatives, and technological innovations underpin HEPZATO’s market potential.
• Financial Outlook: Projected revenue growth from initial launch ($50 million in 2023) to over $700 million by 2026, with significant market share expansion.
• Strategic Positioning: Differentiation through efficacy, dosing schedule, and thermostability; partnerships with global health organizations are crucial.
• Regulatory Pathways: Timely approvals from FDA, EMA, and WHO are pivotal; regional registration strategies are necessary for global reach.
• Challenges & Risks: Regulatory delays, manufacturing scalability, and market competition require strategic oversight.
• Opportunities: Inclusion in GAVI, UNICEF procurement, and expanding emerging markets will drive growth.

By leveraging its innovative profile, HEPZATO exhibits potential to reshape hepatitis B immunization, especially in areas underserved by existing vaccines. A focused approach on regulatory navigation, manufacturing capacity, and global partnerships will define its financial trajectory and market impact.

---

References

1. WHO. (2022). Hepatitis B fact sheets. World Health Organization.
2. Gavi. (2023). Vaccine procurement & market data. Global Alliance for Vaccines and Immunization.
3. FDA. (2023). Hepatitis B vaccine approvals and policies. U.S. Food and Drug Administration.
4. EMA. (2023). European Medicines Agency updates on vaccine approvals.
5. Market research reports from GlobalData and IQVIA on hepatitis vaccines, 2023.